Search results
Added:
9 years ago
Added:
9 years ago
Added:
7 months ago
ESC 2023 — Dr Robert Mentz (Duke University Medical Center, US) joins us to provide a succinct summary of the findings and key take-home messages from the HEART-FID study (NCT03037931).
HEART-FID(American Regent, Inc.) aimed to determine the safety and efficacy of iron therapy using intravenous (IV) ferric carboxymaltose (FCM) as compared to a placebo in the treatment of patients with heart…
View more
Added:
10 months ago
ESC-HFA 23 – Prof Paul Kalra (Portsmouth Hospitals NHS Trust, UK) joins us onsite to discuss the IRONMAN trial (NCT02642562).
The IRONMAN trial aimed to study the effectiveness of intravenous iron in patients with heart failure and iron deficiency when compared to standard care. It showed that administration of IV FDI led to lower rates of recurrent heart failure hospitalisations and…
View more
Added:
4 years ago
We are joined on site by Dr Piotr Ponikowski at HFA 2019 to discuss the management of iron deficiency in Heart Failure, and how to implement best practices to improve patient outcomes.
View more
Added:
3 years ago
Iron is an essential trace element that is present in a number of molecular systems, and it is increasingly recognised as an important cofactor for a variety of cell systems.1 It has been acknowledged that iron plays an important role in oxygen transport, as well as in cell growth and proliferation. In recent years, more insight has been gained into iron physiology and the regulation of cellular…
View more
Added:
2 years ago
Added:
2 years ago
In this short video, Dr Benedikt Schrage (University Heart and Vascular Center Hamburg, DE) summarises the main findings from the analysis that looked into the association between AID/FID with incident CV disease and mortality in 2 164 individuals from three European population-based cohorts. The study, published in the ESC Heart Failure (2021), found that attributable risks ofFID for the tested…
View more
Added:
3 years ago
Despite advances in the management of heart failure (HF), a significant burden of mortality and morbidity remains.1 This, combined with the ever-escalating costs of novel drug development, has led to an increased focus on the treatment of comorbidities in order to improve outcomes. As a chronic condition, it is increasingly recognised that HF is actually an iron-deficient state, and is highly…
View more
Added:
1 year ago
Iron deficiency is common in heart failure, particularly in hospitalised patients and may exacerbate symptoms and increase the risk of hospitalisation and premature mortality. Although previous studies have shown that intravenous iron provides improvement in exercise capacity and reduces hospitalisation in patients with HF and iron deficiency, longer term efficacy and safety data has been lacking…
View more
